FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar
Executive Summary
Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.
You may also be interested in...
US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
Amgen Withdraws EU Application For Its Infliximab Biosimilar
In a change of strategy, Amgen has withdrawn its European application for biosimilar infliximab.